美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Renaissance International IPO ETF

21.97

-0.2309-1.04%

盤後：22.270.2961+1.35%16:10 EDT

成交量：4,466

成交額：9.86萬

市值：1,098.70萬

市盈率：- -

高：22.27

開：22.10

低：21.97

收：22.20

52周最高：26.25

52周最低：15.65

股本：50.00萬

流通股本：50.00萬

量比：2.53

換手率：0.89%

股息：0.15

股息率：0.66%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

AI 計算網絡製造商 Ligent Technologies 計劃在香港進行 IPO，合計募資最高達 57 億港元

正裕工業：3568.60萬股定增限售股9月21日上市流通

據報OpenAI明確今年不會推進上市

波士頓動力2027年IPO料難成行人形機器人商業化前路漫漫

瓦軸B(200706.SZ)：向深圳證券交易所提出終止上市申請

宇樹科技跌1.49%創新低上個月上市募資61億元

超900元/桶！原油再破上市新高，強在哪了？

萊美藥業(300006.SZ)子公司非奈利酮原料藥獲批上市

瓦軸B：擬向深交所申請主動終止股票上市

辰欣藥業(603367.SH)子公司藥品氯替潑諾妥布黴素滴眼液首仿獲批上市

破發股凱賽生物跌4.97% A股共募115億IPO中信證券保薦

破發股三元生物跌2.9% 上市即頂超募26億中信建投保薦

破發股威邁斯跌4.72% 上市即巔峯募20億東方證券保薦

宇樹科技跌1.49%創新低上個月上市募資61億元

辰欣藥業：子公司氯替潑諾妥布黴素滴眼液首仿獲批上市

萊美藥業：全資子公司獲得非奈利酮原料藥上市批准

彤程新材：董事會審議通過H股發行上市相關事宜

【新股IPO】海柔創新再推港股IPO進程龍頭光環下暗藏盈利與負債困境

港股異動 | 亮晴控股(03774)盤中升逾31% 公司轉主板上市兩月有餘本月初正式進入港股通名單

曝DeepSeek來了位90後CFO

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/IPOS/news?page=13"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IPOS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IPOS\",,,,,undefined,":{"symbol":"IPOS","market":"US","secType":"STK","nameCN":"Renaissance International IPO ETF","latestPrice":21.9739,"timestamp":1789588800000,"preClose":22.2048,"halted":0,"volume":4466,"hourTrading":{"tag":"盘后","latestPrice":22.27,"preClose":21.9739,"latestTime":"16:10 EDT","volume":6,"amount":131.8434,"timestamp":1789589404236,"change":0.2961,"changeRate":0.013475,"amplitude":0},"delay":0,"changeRate":-0.010398652543594103,"floatShares":500001,"shares":500001,"eps":0,"marketStatus":"未開盤","change":-0.2309,"latestTime":"09-16 16:00:00 EDT","open":22.1,"high":22.27,"low":21.97,"amount":98576,"amplitude":0.013511,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789632000000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":22.2048,"sharesOutstanding":400001,"nav":22.2869,"aum":11143472.21,"dividendRate":0.006599,"bidAskSpread":0.005267,"postHourTrading":{"tag":"盘后","latestPrice":22.27,"preClose":21.9739,"latestTime":"16:10 EDT","volume":6,"amount":131.8434,"timestamp":1789589404236,"change":0.2961,"changeRate":0.013475,"amplitude":0},"volumeRatio":2.5303116290669214,"impliedVol":0.8998,"impliedVolPercentile":0.992},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IPOS\",,,,,undefined,":{"symbol":"IPOS","floatShares":500001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.5303116290669214,"shares":500001,"dividePrice":0.145,"high":22.27,"amplitude":0.013511,"preClose":22.2048,"low":21.97,"week52Low":15.65,"pbRate":"--","week52High":26.25,"institutionHeld":0,"latestPrice":21.9739,"eps":0,"divideRate":0.006599,"volume":4466,"delay":0,"ttmEps":0,"open":22.1,"prevYearClose":16.8936,"prevWeekClose":22.665,"prevMonthClose":23.3188,"prevQuarterClose":25.635,"fiveDayClose":23.2152,"twentyDayClose":23.3147,"sixtyDayClose":26.1608},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IPOS\",params:#limit:5,,,undefined,":[{"date":"2026-09-11","symbol":"IPOS","amount":0.072205,"announcedDate":"2026-09-10","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-11","defaultRemindTime":1789133400000,"name":"Renaissance International IPO ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-18","payableDate":"2026-09-11","currency":"USD","dateTimestamp":1789099200000,"payDate":"2026-09-18"},{"date":"2026-06-12","symbol":"IPOS","amount":0.054103,"announcedDate":"2026-06-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-12","defaultRemindTime":1781271000000,"name":"Renaissance International IPO ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-22","payableDate":"2026-06-12","currency":"USD","dateTimestamp":1781236800000,"payDate":"2026-06-22"},{"date":"2025-12-12","symbol":"IPOS","amount":0.017941,"announcedDate":"2025-12-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-12","defaultRemindTime":1765549800000,"name":"Renaissance International IPO ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-12","currency":"USD","dateTimestamp":1765515600000,"payDate":"2025-12-19"},{"date":"2025-09-12","symbol":"IPOS","amount":0.007352,"announcedDate":"2025-09-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-12","defaultRemindTime":1757683800000,"name":"Renaissance International IPO ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-19","payableDate":"2025-09-12","currency":"USD","dateTimestamp":1757649600000,"payDate":"2025-09-19"},{"date":"2025-06-13","symbol":"IPOS","amount":0.13555,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-13","defaultRemindTime":1749821400000,"name":"Renaissance International IPO ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-13","currency":"USD","dateTimestamp":1749787200000,"payDate":"2025-06-20"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IPOS\",market:\"US\",,,undefined,":[{"executeDate":"2016-09-16","recordDate":"2016-09-20","paymentDate":"2016-09-26","value":0.10823,"currency":"USD"},{"executeDate":"2017-06-16","recordDate":"2017-06-20","paymentDate":"2017-06-26","value":0.15245,"currency":"USD"},{"executeDate":"2017-09-15","recordDate":"2017-09-18","paymentDate":"2017-09-22","value":0.05857,"currency":"USD"},{"executeDate":"2018-03-16","recordDate":"2018-03-19","paymentDate":"2018-03-23","value":0.00775,"currency":"USD"},{"executeDate":"2018-06-15","recordDate":"2018-06-18","paymentDate":"2018-06-22","value":0.2024,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IPOS\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IPOS\",pageSize:20,pageCount:13,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667654275","title":"AI 計算網絡製造商 Ligent Technologies 計劃在香港進行 IPO，合計募資最高達 57 億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667654275","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667654275?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 17:23","pubTimestamp":1789377827,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据彭博社报道，AI 计算网络制造商 Ligent Technologies Inc. 计划在香港进行 IPO，拟发行 1.72 亿股股票，发行价每股 32.96 港元，合计募资最高达 57 亿港元（约 7.27 亿美元）。该公司总部位于美国加州圣何塞，为中资背景企业。股票预计于 9 月 22 日正式挂牌交易。 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2289637","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTY","BK4127","FRHC","QTOC","REDS","VTHR","AGIX","IPOS","AIPO","CHAT","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667565482","title":"正裕工業：3568.60萬股定增限售股9月21日上市流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2667565482","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667565482?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 17:18","pubTimestamp":1789377534,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667651054","title":"據報OpenAI明確今年不會推進上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2667651054","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667651054?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 17:05","pubTimestamp":1789376755,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据外媒报道，OpenAI首席执行官萨姆·阿尔特曼在周末接受采访时明确指出，ChatGPT的母公司OpenAI今年不会进行首次公开募股（IPO），并直接回应称在当前的评估阶段推进上市是“不明智的”。阿尔特曼随后在社交平台X上进一步解释，前沿人工智能的研发需要循序渐进，而非盲目冲刺或停滞不前。该表态反映了近期AI行业领袖对安全性和负责任研发的共同诉求。有分析人士认为，投资者此前对AI领军企业的资本运作寄予厚望。OpenAI延缓上市进程，加上市场对行业研发速度放缓及合规成本上升的担忧，直接打压了风险偏好。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/NjEzNTY0MzU5MDE2.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NjEzNTY0MzU5MDE2.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305983","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667597216","title":"波士頓動力2027年IPO料難成行 人形機器人商業化前路漫漫","url":"https://stock-news.laohu8.com/highlight/detail?id=2667597216","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667597216?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:41","pubTimestamp":1789375273,"startTime":"0","endTime":"0","summary":"现代汽车集团尚未公开披露波士顿动力潜在上市的时间表或估值目标。集团未立即回应置评请求，波士顿动力在非营业时间亦无法置评。IPO或仍需数年分析师认为，波士顿动力未来几年不太可能上市，因人形机器人仍无法在工厂广泛部署。文件显示，2021年至2025年，波士顿动力累计亏损近1.7万亿韩元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495626.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["UBOT","WDRN","IQM","FRHC","RTOO","IPOS","BK4127","KCE","REDS","ROBT","PBOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667695651","title":"瓦軸B(200706.SZ)：向深圳證券交易所提出終止上市申請","url":"https://stock-news.laohu8.com/highlight/detail?id=2667695651","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667695651?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:37","pubTimestamp":1789375022,"startTime":"0","endTime":"0","summary":"格隆汇9月14日丨瓦轴B(200706.SZ)公布，根据中国证券登记结算有限责任公司深圳分公司的统计，截至2026年2月27日，瓦轴B预受要约的股东为1,459户，预受要约的无限售条件流通社会公众股份数量合计54,524,555股。根据《瓦房店轴承股份有限公司要约收购报告书》约定的生效条件，本次要约收购生效。\n\n　　在本次预受要约股份过户完成后，由于社会公众持有的股份数量占公司股份总数比例低于10%，根据《证券法》《深圳证券交易所股票上市规则》等相关法规的规定,公司的股权分布已不再具备上市条件。根据相关法规的规定，公司向深圳证券交易所提出终止上市的申请。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260914/32369058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IPOS","399001"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667665643","title":"宇樹科技跌1.49%創新低 上個月上市募資61億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667665643","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667665643?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:17","pubTimestamp":1789373822,"startTime":"0","endTime":"0","summary":"中国经济网北京9月14日讯 宇树科技 今日盘中最低报465.58元，创上市以来股价新低。截至今日收盘，宇树科技报470元，跌幅1.49%。宇树科技上市首日开盘报1100元，若以上市当日开盘价买入宇树科技，今日收盘时亏损57.27%。　　宇树科技2026年8月19日在上交所科创板上市，发行股票数量4,044.6434万股，发行价格为150.80元/股。　　宇树科技本次发行募集资金总额609,932.22万元；扣除发行费用后，募集资金净额为591,714.92万元。宇树科技最终募集资金净额较原计划多171,543.8万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260914/32369038.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667596816","title":"超900元/桶！原油再破上市新高，強在哪了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2667596816","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667596816?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:17","pubTimestamp":1789373820,"startTime":"0","endTime":"0","summary":"风险提示油价的波动还有可能进一步上升，交易者应严控风险，谨慎参与。受到地缘冲突升级的影响，国内原油价格大幅上行，截至9月14日收盘，SC原油价格最高至910元/桶，创下了自2018年3月26日上市以来的最高价，初步估算溢价同时刻的Brent价格约25美元/桶，SC为何如此强？9月11日前后，沙特宣布因遭受无人机的袭击，东西管线预防性停输。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/future/2026-09-14/doc-inirutpa4609441.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["UCO","WTIU","FTXN","OILU","DRLL","IXC","BK4585","OILK","DBC","GUSH","UGA","USOI","SCO","DIG","DRIP","XES","DBO","FLBR","CLmain","USL","XOP","OIH","BZmain","PXE","USO","OILT","IEO","ERX","PXJ","DDG","DUG","BK4588","MCLmain","BNO","DWT","DBE","QMmain","USE","VDE","FAAR","BK4570","IPOS","FBZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667327659","title":"萊美藥業(300006.SZ)子公司非奈利酮原料藥獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2667327659","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667327659?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:14","pubTimestamp":1789373691,"startTime":"0","endTime":"0","summary":"智通财经APP讯，莱美药业(300006.SZ)发布公告，近日，公司全资子公司重庆莱美隆宇药业有限公司(简称莱美隆宇)收到国家药品监督管理局核准签发的非奈利酮《化学原料药上市申请批准通知书》。非奈利酮是一种非甾体选择性盐皮质激素受体(MR)拮抗剂，其制剂用于治疗与2型糖尿病相关的慢性肾病成人患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495603.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","BK0070","300006","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667659880","title":"瓦軸B：擬向深交所申請主動終止股票上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2667659880","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667659880?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:14","pubTimestamp":1789373664,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667656246","title":"辰欣藥業(603367.SH)子公司藥品氯替潑諾妥布黴素滴眼液首仿獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2667656246","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667656246?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:05","pubTimestamp":1789373101,"startTime":"0","endTime":"0","summary":"智通财经APP讯，辰欣药业(603367.SH)发布公告，近日，公司子公司山东辰欣佛都药业股份有限公司(简称“佛都药业”)收到国家药品监督管理局核准签发的氯替泼诺妥布霉素滴眼液《药品注册证书》。氯替泼诺妥布霉素滴眼液注册分类为化学药品4类，主要用于治疗对类固醇有反应的眼部炎症，及其伴随的或潜在的眼表面细菌感染。佛都药业氯替泼诺妥布霉素滴眼液首次提交注册申请获得受理的时间为2025年，本次为国内首仿上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","603367","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667656273","title":"破發股凱賽生物跌4.97% A股共募115億IPO中信證券保薦","url":"https://stock-news.laohu8.com/highlight/detail?id=2667656273","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667656273?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:01","pubTimestamp":1789372863,"startTime":"0","endTime":"0","summary":"中国经济网北京9月14日讯 凯赛生物 今日收报37.88元，跌幅4.97%。该股目前处于破发状态。　　凯赛生物于2020年8月12日在上交所科创板上市，公开发行股份总数为4,166.8198万股，占发行后股份总数的10.00%，发行价格为133.45元/股，保荐人为中信证券股份有限公司，保荐代表人为先卫国、黄艺彬。　　上市首日，凯赛生物盘中最高价198元，为该股上市以来最高价。　　凯赛生物上述2次募集资金合计114.87亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260914/32369019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU2148510915.USD","LU2580892862.HKD","83130","600030","BK0196","BK0028","LU1781817850.SGD","LU2289578879.USD","LU1328615791.USD","BK4127","BK0208","83188","LU1146622755.USD","LU2580892789.USD","688065","LU1255011170.USD","BK0276","LU1064131003.USD","LU1655091616.SGD","KCE","LU2495084118.USD","LU1720050803.USD","IPOS","LU1997245094.SGD","LU1997245177.USD","07233","BK1516","BK1564","LU0405327148.USD","LU1794554557.SGD","02846","03188","BK1521","BK1147","REDS","02827","BK0012","159982","BK0188","06030","399300","BK0183","LU0405327494.USD","LU1580142542.USD","LU1820825898.SGD","LU1997244956.HKD","FRHC","82846","LU1064130708.USD","03130"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667562226","title":"破發股三元生物跌2.9% 上市即頂超募26億中信建投保薦","url":"https://stock-news.laohu8.com/highlight/detail?id=2667562226","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667562226?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:01","pubTimestamp":1789372863,"startTime":"0","endTime":"0","summary":"中国经济网北京9月14日讯 三元生物 今日股价下跌，截至收盘报24.14元，跌幅2.90%。　　上市首日，三元生物创下上市以来最高价报146.00元。　　三元生物首次公开发行股票的发行费用总额为1.39亿元，其中，保荐及承销费用1.21亿元。　　2022年6月10日，三元生物披露了2021年年度权益分派实施公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260914/32369018.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IPOS","601066","BK0276","301206","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667562786","title":"破發股威邁斯跌4.72% 上市即巔峯募20億東方證券保薦","url":"https://stock-news.laohu8.com/highlight/detail?id=2667562786","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667562786?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:01","pubTimestamp":1789372862,"startTime":"0","endTime":"0","summary":"中国经济网北京9月14日讯 威迈斯 今日收报37.75元，跌幅4.72%。该股目前处于破发状态。　　威迈斯于2023年7月26日在上交所科创板上市，发行股票数量4,210.00万股，发行价格为47.29元/股，保荐人为东方证券承销保荐有限公司，保荐代表人为王德慧、姜晓华。　　上市首日，威迈斯盘中最高价报62.00元，为该股上市以来最高价。　　威迈斯首次公开发行股票的发行费用合计15,509.36万元，其中，承销保荐费用11,547.27万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260914/32369017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["03958","BK0188","BK1147","BK0012","BK1564","IPOS","BK0028","600958","BK0264","688612","BK0183","BK0276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667220656","title":"宇樹科技跌1.49%創新低 上個月上市募資61億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667220656","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667220656?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:01","pubTimestamp":1789372862,"startTime":"0","endTime":"0","summary":"中国经济网北京9月14日讯 宇树科技 今日盘中最低报465.58元，创上市以来股价新低。截至今日收盘，宇树科技报470元，跌幅1.49%。宇树科技上市首日开盘报1100元，若以上市当日开盘价买入宇树科技，今日收盘时亏损57.27%。　　宇树科技2026年8月19日在上交所科创板上市，发行股票数量4,044.6434万股，发行价格为150.80元/股。　　宇树科技本次发行募集资金总额609,932.22万元；扣除发行费用后，募集资金净额为591,714.92万元。宇树科技最终募集资金净额较原计划多171,543.8万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260914/32369016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667656123","title":"辰欣藥業：子公司氯替潑諾妥布黴素滴眼液首仿獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2667656123","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667656123?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:00","pubTimestamp":1789372838,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667699656","title":"萊美藥業：全資子公司獲得非奈利酮原料藥上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2667699656","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667699656?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:57","pubTimestamp":1789372642,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667465666","title":"彤程新材：董事會審議通過H股發行上市相關事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=2667465666","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667465666?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:56","pubTimestamp":1789372588,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667493656","title":"【新股IPO】海柔創新再推港股IPO進程 龍頭光環下暗藏盈利與負債困境","url":"https://stock-news.laohu8.com/highlight/detail?id=2667493656","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667493656?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:54","pubTimestamp":1789372472,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所9月13日披露，海柔创新更新招股书，继续推进港股IPO上市进程，高盛、中信证券为联席保荐人。依托先发技术优势与持续迭代的产品体系，海柔创新在全球ACR市场的龙头地位持续巩固。截至2026年7月末，海柔创新的赎回负债达52.76亿元，占流动负债比例超过66.8%，而这笔负债每年产生的利息就将近2亿元，正持续侵蚀利润。海柔创新虽然在全球ACR市场占据超过30%的份额，但行业仍处于快速演变之中。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/YzZkNGQ5YjgxMTczNjIxODI3MDA4NQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/YzZkNGQ5YjgxMTczNjIxODI3MDA4NQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991562","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FRHC","BK4588","IPOS","VXUS","KCE","REDS","BK4127","BK4585","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667492656","title":"港股異動 | 亮晴控股(03774)盤中升逾31% 公司轉主板上市兩月有餘 本月初正式進入港股通名單","url":"https://stock-news.laohu8.com/highlight/detail?id=2667492656","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667492656?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:52","pubTimestamp":1789372341,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亮晴控股盘中涨超31%。消息面上，上交所近期宣布调整沪港通下港股通标的，亮晴控股正式进入港股通名单，已于9月7日起生效。值得注意的是，6月30日，亮晴控股成功从GEM转至主板上市。公司转主板两月有余便进入港股通名单，有助于进一步优化投资者结构、提升股票流动性及企业品牌价值。值得一提的是，今年7月，亮晴控股“AI抗衰老”平台开发启动，委聘香港AI企业Sunseeker开发模型。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","KCAI","03774","BK4588","BK1215","BK4585","FLHK","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667594236","title":"曝DeepSeek來了位90後CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2667594236","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667594236?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:52","pubTimestamp":1789372320,"startTime":"0","endTime":"0","summary":"此前报道称，DeepSeek已聘请中信证券，为其科创板IPO筹备相关工作。9月14日消息，今日，据TOP华人科创社报道，高瓴创投90后合伙人严文韬或将加入DeepSeek出任CFO。倘若此事属实，这将成为DeepSeek创立以来，一次重量级的非技术高管引进。腾讯和宁德时代由此成为DeepSeek最大的外部股东。产品方面，DeepSeek的布局也已提速。资本、产品双线推进的同时，近段时间DeepSeek接连被曝出CFO即将就位、已聘请中信证券准备上市筹备配套工作，都预示其IPO进程正在提速。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-14/doc-inirutnu9432322.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IPO","IPOS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":54,"pageCount":13,"totalSize":1062,"code":"91000000","status":"200"}]}}